Phibro Animal Health | PAHC - 营业利润



金融业
股票价格
USD
资产
USD 1.5B
现金及等价物
USD 61.42M
销售成本
USD 240.42M
流动资产
USD 935.51M
流动负债
USD 316.47M
债务
USD 474.17M
股息收益率
1.29
EBIT
USD 54.99M
EBITDA
USD 68.1M
员工
1.92K
EPS每股收益
USD 0.78
股本和储备
USD 385.48M
销售毛利
USD 133.5M
债务利息支出
USD 11.91M
利息收入
USD 0.08
贷款资金
USD 597.69M
市值
USD 1.52B
净收入
USD 27.46M
营业费用
USD 361.83M
营业利润
USD 54.99M
普通股股本
USD 40.48M
PE价格收益
13.82
税前利润
USD 38.63M
销售收入
USD 373.91M
销售和管理费用
USD 78.32M
股票
USD 534.88M
贸易债权人
USD 127.31M
应收帐款人
USD 215.87M


营业利润 更改 日
Align Technology USD 191.32M 13.27M 2026-06
ANI Pharmaceuticals USD 39.84M 1.13M 2026-06
Aurora Cannabis CAD -10.03M 25.76M 2026-03
Bristol-Myers Squibb USD 299M 3.07B 2026-06
Canopy Growth CAD -27.47M 14.81M 2026-03
Corcept Therapeutics USD 41.3M 90.9M 2026-06
Eli Lilly USD 12.46B 2.68B 2026-06
Henry Schein USD 200M 18M 2026-06
Idexx Laboratories USD 425.57M 62.98M 2026-06
Knight Therapeutics CAD 6.21M 3.27M 2025-12
Merck USD 840M 2.72B 2026-06
Nektar Therapeutics USD -38.26M 19.17M 2026-03
Pacira USD 9.96M 5.33M 2026-06
Phibro Animal Health USD 54.99M 2.36M 2025-12
Prestige Brands USD 52.52M 22.97M 2026-06
Supernus Pharmaceuticals USD -21.04M 14.21M 2026-06
Zoetis USD 1.12B 256M 2026-06